ALMS Alumis Inc.
Legal ·
Alumis (Nasdaq: ALMS) inherited Boukadoum v. Acelyrin in its May 2025 merger. The filing names ACELYRIN and unnamed officers and directors; ACELYRIN's 2024 signers are listed.
Alumis sold 17.65 million shares at $17 after two phase 3 trials of its oral TYK2 inhibitor envudeucitinib met all endpoints. A prospectus had flagged going-concern doubt before the deal.
Alumis Inc. says the merger closed May 21, 2025, making ACELYRIN a wholly owned subsidiary. Alumis says its cash runway now extends into 2027, and Lynn Tetrault joined its board.
The closing release uses 0.4814 shares per ACELYRIN share, while the merger agreement and Alumis's annual report set 0.4274, and the release does not explain the gap.
ACELYRIN holders would receive 0.4274 Alumis shares for each share and own about 45% of the combined company. The cash figures behind the deal are preliminary and unaudited, and ACELYRIN's lead program is being re-evaluated.
ACELYRIN holders would receive 0.4274 Alumis shares for each share they own, and the $737 million pro forma cash figure rests on preliminary year-end balances.
Alumis Inc. is a clinical-stage biopharmaceutical company developing Tyrosine Kinase 2 (TYK2) inhibitors for immune-mediated diseases. Its most advanced candidate, envudeucitinib (envu, formerly ESK-001), is an allosteric TYK2 inhibitor studied in plaque psoriasis and systemic lupus erythematosus. The company reported positive topline results from the pivotal Phase 3 ONWARD1 and ONWARD2 trials in plaque psoriasis in the first quarter of 2026, and it plans to submit a New Drug Application to the FDA in the second half of 2026. A Phase 2 lupus trial is expected to report topline results in the third quarter of 2026. A-005 is a CNS-penetrant allosteric TYK2 inhibitor intended for neuroinflammatory and neurodegenerative diseases, including multiple sclerosis, Alzheimer disease, amyotrophic lateral sclerosis and Parkinson disease. Through the ACELYRIN merger, which closed on May 21, 2025, the company also acquired lonigutamab, an IGF-1R antibody for Thyroid Eye Disease. Alumis also has earlier-stage targets, including IRF5, and says it plans to evaluate strategic collaborations for its lead programs.
| Product or program | What it is | Stage |
|---|---|---|
| envudeucitinib (envu, ESK-001) | Second-generation allosteric TYK2 inhibitor for psoriasis and lupus | Phase 3 pivotal trials; NDA planned for second half of 2026 |
| A-005 | CNS-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases | Phase 1 program initiated April 2024 |
| lonigutamab | Subcutaneously delivered monoclonal antibody targeting IGF-1R for Thyroid Eye Disease | |
| IRF5 targets | Earlier-stage targets selected for broad indications | Lead identification to lead optimization |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $24.1 million | |
| Research and development | $386.0 million | $265.6 million |
| Net income (loss) | -$243.3 million | -$294.2 million |
| Cash from operations | -$369.5 million | -$255.1 million |
| Cash and equivalents | $89.7 million | $169.5 million |
| Short-term investments | $218.8 million | $118.7 million |
Our latest story on this, dated Aug 13, 2026: "Alumis carries ACELYRIN securities class action over izokibep trial; dismissal motion pending". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 7, 2026: "Alumis raises $300 million a day after psoriasis pill beats placebo and apremilast in phase 3". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 7, 2026: "Alumis raises $300 million a day after psoriasis pill beats placebo and apremilast in phase 3". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 13, 2026: "Alumis carries ACELYRIN securities class action over izokibep trial; dismissal motion pending". The story links the filing or release it is based on. Read the story.
Alumis Inc. trades under the ticker ALMS on NASDAQ.
Alumis Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Alumis Inc. is 1847367. Its filings are on SEC EDGAR.
Our directory records Alumis Inc. under United States.
Our directory classifies Alumis Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Alumis Inc. is US0223071020.
aibio.space lists Alumis Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Alumis Inc. is a clinical-stage biopharmaceutical company developing Tyrosine Kinase 2 (TYK2) inhibitors for immune-mediated diseases. Its most advanced candidate, envudeucitinib (envu, formerly ESK-001), is an allosteric TYK2 inhibitor studied in plaque psoriasis and systemic lupus erythematosus.
envudeucitinib (envu, ESK-001): Second-generation allosteric TYK2 inhibitor for psoriasis and lupus Stage: Phase 3 pivotal trials; NDA planned for second half of 2026.
A-005: CNS-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases Stage: Phase 1 program initiated April 2024.
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,5.02,8.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.02,7.01,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio